\-\ Texto\\:\\ \ \(0\)\
\-\ negative\\ clinical\\ breast\\ exam\\ by\\ experienced\\ surgeon\\,\\ negative\\ screening\\ mammography\\.\\ genetics\\ testing\\ revealed\\ brca\\-1\\ positivity\\.\ \(0\)\
\-\ patient\\ will\\ undergo\\ lymphoscintigraphy\\ for\\ sentinal\\ node\\ biopsy\\.\\ if\\ no\\ metastases\\,\\ she\\ will\\ likely\\ opt\\ for\\ breast\\ conservation\\ therapy\\ to\\ include\\ lumpectomy\\ and\\ radiation\\.\\ \\ she\\ is\\ considering\\ the\\ option\\ of\\ bilateral\\ mastectomy\\.\\ \\ she\\ will\\ require\\ continued\\ close\\ monitoring\\ for\\ development\\ of\\ additional\\ disease\\.\ \(0\)\
\-\ initial\\ screening\\ two\\ view\\ mammogram\\ was\\ negative\\ for\\ suspicious\\ calcifications\\ or\\ mass\\.\\ \\ the\\ brest\\ tissue\\ was\\ heterogenously\\ dense\\.\ \(0\)\
\-\ patient\\ underwent\\ routine\\ screeing\\ breast\\ mr\\ which\\ demonstrates\\ a\\ small\\ enhancing\\ mass\\ within\\ the\\ mid\\ right\\ breast\\,\\ 12\\:00\\ position\\.\\ \\ there\\ is\\ minimal\\ associated\\ t2\\ hyperintensity\\,\\ but\\ this\\ involves\\ more\\ the\\ periphery\\ of\\ the\\ lesion\\,\\ rather\\ than\\ the\\ substance\\ of\\ the\\ lesion\\ itslef\\.\\ \\ no\\ other\\ discordant\\ foci\\ of\\ abnormal\\ enhancement\\ were\\ present\\ within\\ either\\ breast\\.\ \(0\)\
\-\ the\\ patient\\ was\\ recalled\\ for\\ subsequent\\ right\\ breast\\ ultrasound\\.\\ \\ this\\ demonstrates\\ an\\ angulated\\,\\ hypoechoic\\ 5mm\\ mass\\ in\\ at\\ the\\ 12\\:00\\ position\\,\\ zone\\ 1a\\.\ \(0\)\
\-\ subsequent\\ ultrasound\\-guided\\ 14ga\\ core\\ biopsy\\ was\\ performed\\.\ \(0\)\
\-\ infiltrating\\ ductal\\ carcinoma\ \(11\)\
\-\ atypical\\ fibroadenoma\ \(0\)\
\-\ ductal\\ carcinoma\\ in\\ situ\ \(4\)\
\-\ infiltrating\\ carcinoma\ \(0\)\
\-\ atypical\\ lymph\\ node\ \(0\)\
\-\ atypical\\ papilloma\ \(0\)\
\-\ granular\\ cell\\ tumor\ \(4\)\
\-\ 32\\ year\\-old\\ female\\,\\ asymptomatic\\ with\\ respect\\ to\\ the\\ breasts\\.\\ \\ \\ patient\\ has\\ a\\ mother\\ and\\ sister\\ with\\ breast\\ cancer\\ before\\ age\\ 45\\.\\ \\ she\\ is\\ 10\\ months\\ postpartum\\,\\ is\\ no\\ longer\\ lactating\\,\\ but\\ is\\ trying\\ to\\ get\\ pregnant\\.\ \(0\)\
\-\ the\\ issue\\ of\\ screening\\ high\\ risk\\ patients\\ with\\ breast\\ mr\\ has\\ been\\ discussed\\ for\\ several\\ years\\.\\ \\ it\\ has\\ taken\\ some\\ time\\ for\\ vendors\\ to\\ develop\\ the\\ software\\ necessary\\ to\\ accurately\\ and\\ efficiently\\ use\\ existing\\ mr\\ technology\\ for\\ a\\ screening\\ population\\.\\ \\ mr\\ utility\\ has\\ been\\ extensively\\ used\\ for\\ problem\\-solving\\ and\\ for\\ evaluation\\ of\\ the\\ patient\\ with\\ impants\\.\\ \ \(0\)\
\-\ the\\ exquisite\\ contrast\\ sensitivity\\ of\\ mr\\ is\\ balanced\\ in\\ the\\ high\\-risk\\ patient\\ by\\ somewhat\\ decreased\\ specificity\\;\\ many\\ things\\ other\\ than\\ cancer\\ enhance\\,\\ but\\ benign\\ entities\\ often\\ have\\ an\\ intrinsic\\ high\\ t2\\ signal\\ whereas\\ breast\\ cancer\\ does\\ not\\.\ \(0\)\
\-\ sensitivity\\ has\\ been\\ greatly\\ improved\\ with\\ the\\ use\\ of\\ dynamic\\ contrast\\-enhancement\\,\\ and\\ the\\ addition\\ of\\ software\\ tools\\ allowing\\ the\\ creation\\ of\\ a\\ graphical\\ depiction\\ of\\ contrast\\ kinetics\\ within\\ a\\ specified\\ region\\ of\\ interest\\.\\ \\ given\\ that\\ the\\ region\\ is\\ selected\\ appropriately\\,\\ breast\\ cancer\\ tissue\\ will\\ typically\\ exhibit\\ an\\ early\\ wash\\-in\\,\\ and\\ a\\ rapid\\ wash\\-out\\ of\\ contrast\\ enhancement\\.\\ \\ in\\ contradistinction\\,\\ beningn\\ tissue\\ will\\ demonstrate\\ a\\ progressive\\ increase\\ in\\ enhancement\\ or\\ alternatively\\ a\\ plateau\\.\\ \ \(0\)\
\-\ software\\ refinements\\ continue\\ to\\ be\\ made\\ in\\ order\\ to\\ hopefully\\ better\\ define\\ the\\ specific\\ region\\ of\\ interest\\ and\\ therefore\\ yield\\ the\\ best\\ curve\\.\ \(0\)\
\-\ at\\ the\\ time\\ this\\ case\\ was\\ performed\\,\\ the\\ combination\\ fo\\ software\\ and\\ hardware\\ technology\\ necessary\\ to\\ perform\\ adequate\\ screening\\ mr\\ had\\ only\\ been\\ available\\ for\\ approximately\\ 2\\ months\\.\\ \\ this\\ patient\\'s\\ cancer\\ was\\ only\\ detectable\\ initially\\ through\\ this\\ modality\\.\\ \\ the\\ mammogram\\ was\\,\\ even\\ retrospectively\\,\\ negative\\,\\ and\\ there\\ was\\ no\\ palpable\\ abnormality\\ for\\ which\\ to\\ justify\\ an\\ ultrasound\\ \\(although\\ the\\ lesion\\ was\\ in\\ fact\\ visible\\ under\\ ultrasound\\)\\.\\ \\ this\\ cancer\\ almost\\ certainly\\ would\\ have\\ not\\ been\\ found\\ until\\ it\\ was\\ at\\ a\\ much\\ more\\ advanced\\ state\\,\\ and\\ this\\ patient\\'s\\ life\\ may\\ have\\ just\\ been\\ saved\\-\\-\\ a\\ feat\\ that\\ would\\ have\\ likely\\ not\\ been\\ possible\\ just\\ a\\ few\\ months\\ ago\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.056095337078835454\ \(0\)\
\-\ software\\:\\ 0\\.052877039593214284\ \(0\)\
\-\ screening\\:\\ 0\\.0324291319299675\ \(0\)\
\-\ cancer\\:\\ 0\\.0299910882316523\ \(0\)\
\-\ mr\\:\\ 0\\.02898789471828933\ \(0\)\
\-\ been\\:\\ 0\\.02895651997553014\ \(0\)\
\-\ 12\\:00\\:\\ 0\\.024995583468820082\ \(0\)\
\-\ technology\\:\\ 0\\.02444700453705048\ \(0\)\
\-\ will\\:\\ 0\\.023785418312981692\ \(0\)\
\-\ interest\\:\\ 0\\.022244018030266766\ \(0\)\
\-\ atypical\\:\\ 0\\.019769736489021115\ \(0\)\
\-\ negative\\:\\ 0\\.018164556308717966\ \(0\)\
\-\ was\\:\\ 0\\.017585009292058487\ \(0\)\
\-\ sensitivity\\:\\ 0\\.017176278923139585\ \(0\)\
\-\ she\\:\\ 0\\.01707321097120407\ \(0\)\
\-\ infiltrating\\:\\ 0\\.01651648097534114\ \(0\)\
\-\ mammogram\\:\\ 0\\.015867649812373333\ \(0\)\
\-\ brca\\-1\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ opt\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ brest\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ screeing\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ itslef\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ 14ga\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ vendors\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ efficiently\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ impants\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ graphical\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ kinetics\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ beningn\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ refinements\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ hopefully\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ justify\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ feat\\:\\ 0\\.015685975843356757\ \(0\)\
\-\ for\\:\\ 0\\.015568145522620253\ \(0\)\
\-\ conservation\\:\\ 0\\.014452617870830164\ \(0\)\
\-\ 45\\.\\:\\ 0\\.014452617870830164\ \(0\)\
\-\ problem\\-solving\\:\\ 0\\.014452617870830164\ \(0\)\
\-\ balanced\\:\\ 0\\.014452617870830164\ \(0\)\
\-\ wash\\-in\\:\\ 0\\.014452617870830164\ \(0\)\
\-\ ductal\\:\\ 0\\.014334614523788087\ \(0\)\
\-\ has\\:\\ 0\\.014276690128952652\ \(0\)\
\-\ node\\:\\ 0\\.013915457813267147\ \(0\)\
\-\ positivity\\:\\ 0\\.013731149706936634\ \(0\)\
\-\ lymphoscintigraphy\\:\\ 0\\.013731149706936634\ \(0\)\
\-\ sentinal\\:\\ 0\\.013731149706936634\ \(0\)\
\-\ discordant\\:\\ 0\\.013731149706936634\ \(0\)\
\-\ lactating\\:\\ 0\\.013731149706936634\ \(0\)\
\-\ contrast\\-enhancement\\:\\ 0\\.013731149706936634\ \(0\)\
\-\ creation\\:\\ 0\\.013731149706936634\ \(0\)\
\-\ ultrasound\\:\\ 0\\.01353268283811194\ \(0\)\
\-\ necessary\\:\\ 0\\.013470037375708408\ \(0\)\
\-\ tools\\:\\ 0\\.013219259898303571\ \(0\)\
\-\ specified\\:\\ 0\\.013219259898303571\ \(0\)\
\-\ saved\\:\\ 0\\.013219259898303571\ \(0\)\
\-\ have\\:\\ 0\\.013170377781957949\ \(0\)\
\-\ carcinoma\\:\\ 0\\.01292843951965765\ \(0\)\
\-\ region\\:\\ 0\\.012883992316224089\ \(0\)\
\-\ angulated\\:\\ 0\\.012822207315893945\ \(0\)\
\-\ wash\\-out\\:\\ 0\\.012822207315893945\ \(0\)\
\-\ retrospectively\\:\\ 0\\.012822207315893945\ \(0\)\
\-\ just\\:\\ 0\\.01269926815589328\ \(0\)\
\-\ position\\:\\ 0\\.012662003743554152\ \(0\)\
\-\ high\\-risk\\:\\ 0\\.012497791734410041\ \(0\)\
\-\ depiction\\:\\ 0\\.012497791734410041\ \(0\)\
\-\ contradistinction\\:\\ 0\\.012497791734410041\ \(0\)\
\-\ months\\:\\ 0\\.01245876135955552\ \(0\)\
\-\ enhancement\\:\\ 0\\.01222680836008738\ \(0\)\
\-\ 1a\\:\\ 0\\.01222350226852524\ \(0\)\
\-\ patient\\:\\ 0\\.01219347944364965\ \(0\)\
\-\ use\\:\\ 0\\.012019356281292892\ \(0\)\
\-\ recalled\\:\\ 0\\.011985901925776978\ \(0\)\
\-\ extensively\\:\\ 0\\.011985901925776978\ \(0\)\
\-\ this\\:\\ 0\\.011971459952311265\ \(0\)\
\-\ subsequent\\:\\ 0\\.01183836547263278\ \(0\)\
\-\ fo\\:\\ 0\\.011776323570516509\ \(0\)\
\-\ exquisite\\:\\ 0\\.011588849343367352\ \(0\)\
\-\ heterogenously\\:\\ 0\\.01141925827609987\ \(0\)\
\-\ ultrasound\\-guided\\:\\ 0\\.01141925827609987\ \(0\)\
\-\ existing\\:\\ 0\\.01141925827609987\ \(0\)\
\-\ yield\\:\\ 0\\.01141925827609987\ \(0\)\
\-\ things\\:\\ 0\\.011264433761883448\ \(0\)\
\-\ utility\\:\\ 0\\.011122009015133383\ \(0\)\
\-\ curve\\:\\ 0\\.011122009015133383\ \(0\)\
\-\ postpartum\\:\\ 0\\.010990144295998646\ \(0\)\
\-\ trying\\:\\ 0\\.010990144295998646\ \(0\)\
\-\ intrinsic\\:\\ 0\\.010990144295998646\ \(0\)\
\-\ alternatively\\:\\ 0\\.010990144295998646\ \(0\)\
\-\ detectable\\:\\ 0\\.010990144295998646\ \(0\)\
\-\ genetics\\:\\ 0\\.010867381179473822\ \(0\)\
\-\ substance\\:\\ 0\\.010867381179473822\ \(0\)\
\-\ accurately\\:\\ 0\\.010867381179473822\ \(0\)\
\-\ would\\:\\ 0\\.010821946186555478\ \(0\)\
\-\ tissue\\:\\ 0\\.01081185687786082\ \(0\)\
\-\ biopsy\\:\\ 0\\.010788943920415517\ \(0\)\
\-\ certainly\\:\\ 0\\.010644670960694451\ \(0\)\
\-\ granular\\:\\ 0\\.010542965597989918\ \(0\)\
\-\ sister\\:\\ 0\\.010542965597989918\ \(0\)\
\-\ issue\\:\\ 0\\.010542965597989918\ \(0\)\
\-\ greatly\\:\\ 0\\.010542965597989918\ \(0\)\
\-\ entities\\:\\ 0\\.010446760577936046\ \(0\)\
\-\ hardware\\:\\ 0\\.010446760577936046\ \(0\)\
\-\ contrast\\:\\ 0\\.010210546370860704\ \(0\)\
\-\ define\\:\\ 0\\.010185900303573277\ \(0\)\
\-\ exhibit\\:\\ 0\\.01010680464063585\ \(0\)\
\-\ lumpectomy\\:\\ 0\\.010031075789356855\ \(0\)\
\-\ situ\\:\\ 0\\.00988865104260679\ \(0\)\
\-\ specificity\\:\\ 0\\.00988865104260679\ \(0\)\
\-\ dynamic\\:\\ 0\\.009821497434096386\ \(0\)\
\-\ allowing\\:\\ 0\\.009821497434096386\ \(0\)\
\-\ but\\:\\ 0\\.009728665308008208\ \(0\)\
\-\ respect\\:\\ 0\\.009694346252633494\ \(0\)\
\-\ fibroadenoma\\:\\ 0\\.009634023206947229\ \(0\)\
\-\ \\,\\:\\ 0\\.00963381016075756\ \(0\)\
\-\ 5mm\\:\\ 0\\.009575678326479273\ \(0\)\
\-\ appropriately\\:\\ 0\\.009464432139679747\ \(0\)\
\-\ breasts\\:\\ 0\\.009411312988167858\ \(0\)\
\-\ plateau\\:\\ 0\\.009411312988167858\ \(0\)\
\-\ get\\:\\ 0\\.009309607625463324\ \(0\)\
\-\ lesion\\:\\ 0\\.009291220067618086\ \(0\)\
\-\ considering\\:\\ 0\\.009260855002352799\ \(0\)\
\-\ selected\\:\\ 0\\.009213402605409452\ \(0\)\
\-\ only\\:\\ 0\\.009143813731263115\ \(0\)\
\-\ mastectomy\\:\\ 0\\.009035318159578521\ \(0\)\
\-\ whereas\\:\\ 0\\.009035318159578521\ \(0\)\
\-\ pregnant\\:\\ 0\\.008952542331046684\ \(0\)\
\-\ mammography\\:\\ 0\\.00883517939903281\ \(0\)\
\-\ perform\\:\\ 0\\.00872508081590454\ \(0\)\
\-\ within\\:\\ 0\\.008701769083911468\ \(0\)\
\-\ t2\\:\\ 0\\.008607077468862462\ \(0\)\
\-\ time\\:\\ 0\\.00858932821081606\ \(0\)\
\-\ longer\\:\\ 0\\.008588139461569793\ \(0\)\
\-\ state\\:\\ 0\\.008588139461569793\ \(0\)\
\-\ likely\\:\\ 0\\.008577544362760342\ \(0\)\
\-\ option\\:\\ 0\\.00849193444151592\ \(0\)\
\-\ periphery\\:\\ 0\\.00849193444151592\ \(0\)\
\-\ performed\\:\\ 0\\.008478926445648821\ \(0\)\
\-\ core\\:\\ 0\\.008430571138898182\ \(0\)\
\-\ an\\:\\ 0\\.008410426080318362\ \(0\)\
\-\ monitoring\\:\\ 0\\.008400665234420636\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.008371253665112433\ \(0\)\
\-\ modality\\:\\ 0\\.00834232035395268\ \(0\)\
\-\ high\\:\\ 0\\.008322227975362332\ \(0\)\
\-\ discussed\\:\\ 0\\.008313849995684993\ \(0\)\
\-\ continue\\:\\ 0\\.008204316378248278\ \(0\)\
\-\ adequate\\:\\ 0\\.008151978504215727\ \(0\)\
\-\ surgeon\\:\\ 0\\.008101136204493207\ \(0\)\
\-\ zone\\:\\ 0\\.008076249652936731\ \(0\)\
\-\ fact\\:\\ 0\\.008003612652011011\ \(0\)\
\-\ than\\:\\ 0\\.007968145391168234\ \(0\)\
\-\ population\\:\\ 0\\.007933824906186666\ \(0\)\
\-\ experienced\\:\\ 0\\.007888775425787573\ \(0\)\
\-\ better\\:\\ 0\\.00784483839270862\ \(0\)\
\-\ advanced\\:\\ 0\\.00778090243323164\ \(0\)\
\-\ a\\:\\ 0\\.007762629572961946\ \(0\)\
\-\ undergo\\:\\ 0\\.007719184358520091\ \(0\)\
\-\ rapid\\:\\ 0\\.0076791970705271054\ \(0\)\
\-\ combination\\:\\ 0\\.007659535440301866\ \(0\)\
\-\ papilloma\\:\\ 0\\.007640088695582665\ \(0\)\
\-\ order\\:\\ 0\\.007620852190059149\ \(0\)\
\-\ more\\:\\ 0\\.007605609641680306\ \(0\)\
\-\ 32\\:\\ 0\\.0075829920504732334\ \(0\)\
\-\ develop\\:\\ 0\\.0075829920504732334\ \(0\)\
\-\ somewhat\\:\\ 0\\.007474017628336723\ \(0\)\
\-\ close\\:\\ 0\\.007421935097553604\ \(0\)\
\-\ testing\\:\\ 0\\.0073547814890431995\ \(0\)\
\-\ enhance\\:\\ 0\\.0073547814890431995\ \(0\)\
\-\ almost\\:\\ 0\\.0073547814890431995\ \(0\)\
\-\ suspicious\\:\\ 0\\.007322131776110466\ \(0\)\
\-\ improved\\:\\ 0\\.007243036113173039\ \(0\)\
\-\ rather\\:\\ 0\\.007227630307580309\ \(0\)\
\-\ visible\\:\\ 0\\.007197213166371589\ \(0\)\
\-\ dense\\:\\ 0\\.007182197385862933\ \(0\)\
\-\ therefore\\:\\ 0\\.007182197385862933\ \(0\)\
\-\ involves\\:\\ 0\\.007066425867451791\ \(0\)\
\-\ much\\:\\ 0\\.007038622810684743\ \(0\)\
\-\ other\\:\\ 0\\.007009389853033624\ \(0\)\
\-\ is\\:\\ 0\\.007003621794827543\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.0069842870031045275\ \(0\)\
\-\ require\\:\\ 0\\.006957728906633574\ \(0\)\
\-\ mother\\:\\ 0\\.006944597043114673\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.006931561384587852\ \(0\)\
\-\ few\\:\\ 0\\.006842891680410137\ \(0\)\
\-\ to\\:\\ 0\\.00683916899641793\ \(0\)\
\-\ it\\:\\ 0\\.006835759375562337\ \(0\)\
\-\ even\\:\\ 0\\.0067702546794844165\ \(0\)\
\-\ \\'s\\:\\ 0\\.006704792236181654\ \(0\)\
\-\ until\\:\\ 0\\.006677799628006283\ \(0\)\
\-\ under\\:\\ 0\\.006644331065804332\ \(0\)\
\-\ demonstrates\\:\\ 0\\.006642780077057601\ \(0\)\
\-\ life\\:\\ 0\\.006633313325149669\ \(0\)\
\-\ development\\:\\ 0\\.006622363386405224\ \(0\)\
\-\ either\\:\\ 0\\.006622363386405224\ \(0\)\
\-\ not\\:\\ 0\\.006591558745953392\ \(0\)\
\-\ continued\\:\\ 0\\.006547544460705047\ \(0\)\
\-\ foci\\:\\ 0\\.006526733002051682\ \(0\)\
\-\ metastases\\:\\ 0\\.006495965213599616\ \(0\)\
\-\ addition\\:\\ 0\\.006445839098000512\ \(0\)\
\-\ before\\:\\ 0\\.006435981125801908\ \(0\)\
\-\ best\\:\\ 0\\.006397086474889988\ \(0\)\
\-\ increase\\:\\ 0\\.006377953393437564\ \(0\)\
\-\ mid\\:\\ 0\\.006359023859264868\ \(0\)\
\-\ mass\\:\\ 0\\.0063440979018553265\ \(0\)\
\-\ taken\\:\\ 0\\.006340293587046029\ \(0\)\
\-\ specific\\:\\ 0\\.006285257464819412\ \(0\)\
\-\ many\\:\\ 0\\.006249490241828154\ \(0\)\
\-\ initially\\:\\ 0\\.00618857712502701\ \(0\)\
\-\ at\\:\\ 0\\.00618023035319377\ \(0\)\
\-\ the\\:\\ 0\\.006149879212794742\ \(0\)\
\-\ lymph\\:\\ 0\\.006137975816627485\ \(0\)\
\-\ no\\:\\ 0\\.006124157656254818\ \(0\)\
\-\ additional\\:\\ 0\\.006096880238701062\ \(0\)\
\-\ routine\\:\\ 0\\.006096880238701062\ \(0\)\
\-\ made\\:\\ 0\\.006056712405892274\ \(0\)\
\-\ progressive\\:\\ 0\\.006009678140646446\ \(0\)\
\-\ minimal\\:\\ 0\\.005986619164414231\ \(0\)\
\-\ used\\:\\ 0\\.005833067894925198\ \(0\)\
\-\ view\\:\\ 0\\.005704709303881741\ \(0\)\
\-\ which\\:\\ 0\\.005676671128977041\ \(0\)\
\-\ ago\\:\\ 0\\.0056596598234826484\ \(0\)\
\-\ calcifications\\:\\ 0\\.005653316289382122\ \(0\)\
\-\ abnormality\\:\\ 0\\.005609533707883544\ \(0\)\
\-\ year\\-old\\:\\ 0\\.005584990430068001\ \(0\)\
\-\ early\\:\\ 0\\.005560781084773021\ \(0\)\
\-\ risk\\:\\ 0\\.0055074851376496195\ \(0\)\
\-\ palpable\\:\\ 0\\.005389005413878631\ \(0\)\
\-\ typically\\:\\ 0\\.005367305639690342\ \(0\)\
\-\ that\\:\\ 0\\.005252600457504709\ \(0\)\
\-\ in\\:\\ 0\\.005248719948366165\ \(0\)\
\-\ benign\\:\\ 0\\.005247420581909611\ \(0\)\
\-\ underwent\\:\\ 0\\.00521743066811071\ \(0\)\
\-\ given\\:\\ 0\\.005212481125473919\ \(0\)\
\-\ does\\:\\ 0\\.005187937847658374\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0051398441245481975\ \(0\)\
\-\ although\\:\\ 0\\.005135105481453031\ \(0\)\
\-\ 10\\:\\ 0\\.0051256658867382746\ \(0\)\
\-\ possible\\:\\ 0\\.005120964802284826\ \(0\)\
\-\ available\\:\\ 0\\.005111599731031667\ \(0\)\
\-\ by\\:\\ 0\\.005063597520444394\ \(0\)\
\-\ initial\\:\\ 0\\.005038402390176704\ \(0\)\
\-\ radiation\\:\\ 0\\.004989770906694549\ \(0\)\
\-\ several\\:\\ 0\\.004888065543990013\ \(0\)\
\-\ revealed\\:\\ 0\\.004879846779121162\ \(0\)\
\-\ often\\:\\ 0\\.004851376420853474\ \(0\)\
\-\ found\\:\\ 0\\.004791860523936143\ \(0\)\
\-\ enhancing\\:\\ 0\\.004768600592321636\ \(0\)\
\-\ approximately\\:\\ 0\\.004704302182483243\ \(0\)\
\-\ clinical\\:\\ 0\\.004678487188729544\ \(0\)\
\-\ age\\:\\ 0\\.004627954315915136\ \(0\)\
\-\ some\\:\\ 0\\.004617310060261137\ \(0\)\
\-\ there\\:\\ 0\\.004525678136886081\ \(0\)\
\-\ decreased\\:\\ 0\\.004520918866057935\ \(0\)\
\-\ years\\:\\ 0\\.004464845439534666\ \(0\)\
\-\ evaluation\\:\\ 0\\.004416795010367985\ \(0\)\
\-\ two\\:\\ 0\\.004354681917466202\ \(0\)\
\-\ abnormal\\:\\ 0\\.004336463061058561\ \(0\)\
\-\ through\\:\\ 0\\.004318428858400122\ \(0\)\
\-\ include\\:\\ 0\\.0042653976655343175\ \(0\)\
\-\ if\\:\\ 0\\.004125877996050953\ \(0\)\
\-\ cell\\:\\ 0\\.0041071898782588726\ \(0\)\
\-\ therapy\\:\\ 0\\.00406519714633561\ \(0\)\
\-\ signal\\:\\ 0\\.004009029057424873\ \(0\)\
\-\ patients\\:\\ 0\\.003935186119868373\ \(0\)\
\-\ bilateral\\:\\ 0\\.003690067134011466\ \(0\)\
\-\ \\;\\:\\ 0\\.003603952292620273\ \(0\)\
\-\ associated\\:\\ 0\\.003588011675992352\ \(0\)\
\-\ or\\:\\ 0\\.0035641378966679983\ \(0\)\
\-\ tumor\\:\\ 0\\.0035448973338270662\ \(0\)\
\-\ small\\:\\ 0\\.003502802997119428\ \(0\)\
\-\ demonstrate\\:\\ 0\\.003499025162514307\ \(0\)\
\-\ were\\:\\ 0\\.0034524667912632047\ \(0\)\
\-\ present\\:\\ 0\\.0034341792774585066\ \(0\)\
\-\ exam\\:\\ 0\\.0033402739145009575\ \(0\)\
\-\ may\\:\\ 0\\.0033351038592493304\ \(0\)\
\-\ case\\:\\ 0\\.003326520343180197\ \(0\)\
\-\ had\\:\\ 0\\.0032808715644852457\ \(0\)\
\-\ 2\\:\\ 0\\.0032742072891646726\ \(0\)\
\-\ right\\:\\ 0\\.0032086537690762156\ \(0\)\
\-\ and\\:\\ 0\\.003203007219434492\ \(0\)\
\-\ female\\:\\ 0\\.003125907956312871\ \(0\)\
\-\ of\\:\\ 0\\.0031095320497683747\ \(0\)\
\-\ disease\\:\\ 0\\.002485298116042178\ \(0\)\
\-\ be\\:\\ 0\\.0023447628529251405\ \(0\)\
\-\ \\.\\:\\ 0\\.0017686601614336221\ \(0\)\
\-\ \\(\\:\\ 0\\.0012853411499001077\ \(0\)\
\-\ \\)\\:\\ 0\\.0012696400215539236\ \(0\)\
\-\ with\\:\\ 0\\.0010409624207285565\ \(0\)\
